Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16


Discovery and Characterization of VU0529331, a Synthetic Small-Molecule Activator of Homomeric G Protein-Gated, Inwardly Rectifying, Potassium (GIRK) Channels.

Kozek KA, Du Y, Sharma S, Prael FJ 3rd, Spitznagel BD, Kharade SV, Denton JS, Hopkins CR, Weaver CD.

ACS Chem Neurosci. 2018 Sep 13. doi: 10.1021/acschemneuro.8b00287. [Epub ahead of print]


Discovery, Characterization, and Effects on Renal Fluid and Electrolyte Excretion of the Kir4.1 Potassium Channel Pore Blocker, VU0134992.

Kharade SV, Kurata H, Bender AM, Blobaum AL, Figueroa EE, Duran A, Kramer M, Days E, Vinson P, Flores D, Satlin LM, Meiler J, Weaver CD, Lindsley CW, Hopkins CR, Denton JS.

Mol Pharmacol. 2018 Aug;94(2):926-937. doi: 10.1124/mol.118.112359. Epub 2018 Jun 12.


Discovery and in Vitro Optimization of 3-Sulfamoylbenzamides as ROMK Inhibitors.

Sammons MF, Kharade SV, Filipski KJ, Boehm M, Smith AC, Shavnya A, Fernando DP, Dowling MS, Carpino PA, Castle NA, Zellmer SG, Antonio BM, Gosset JR, Carlo A, Denton JS.

ACS Med Chem Lett. 2018 Jan 19;9(2):125-130. doi: 10.1021/acsmedchemlett.7b00481. eCollection 2018 Feb 8.


Plight of the pore polar bar(rier).

Denton JS, Kharade SV.

Channels (Austin). 2017 Nov 2;11(6):502-503. doi: 10.1080/19336950.2017.1367234. Epub 2017 Aug 25. No abstract available.


Pore Polarity and Charge Determine Differential Block of Kir1.1 and Kir7.1 Potassium Channels by Small-Molecule Inhibitor VU590.

Kharade SV, Sheehan JH, Figueroa EE, Meiler J, Denton JS.

Mol Pharmacol. 2017 Sep;92(3):338-346. doi: 10.1124/mol.117.108472. Epub 2017 Jun 15.


BK channels in rat and human pulmonary smooth muscle cells are BKα-β1 functional complexes lacking the oxygen-sensitive stress axis regulated exon insert.

Detweiler ND, Song L, McClenahan SJ, Versluis RJ, Kharade SV, Kurten RC, Rhee SW, Rusch NJ.

Pulm Circ. 2016 Dec;6(4):563-575. doi: 10.1086/688838.


ML418: The First Selective, Sub-Micromolar Pore Blocker of Kir7.1 Potassium Channels.

Swale DR, Kurata H, Kharade SV, Sheehan J, Raphemot R, Voigtritter KR, Figueroa EE, Meiler J, Blobaum AL, Lindsley CW, Hopkins CR, Denton JS.

ACS Chem Neurosci. 2016 Jul 20;7(7):1013-23. doi: 10.1021/acschemneuro.6b00111. Epub 2016 May 24.


The shifting landscape of KATP channelopathies and the need for 'sharper' therapeutics.

Kharade SV, Nichols C, Denton JS.

Future Med Chem. 2016 May;8(7):789-802. doi: 10.4155/fmc-2016-0005. Epub 2016 May 10. Review.


ROMK inhibitor actions in the nephron probed with diuretics.

Kharade SV, Flores D, Lindsley CW, Satlin LM, Denton JS.

Am J Physiol Renal Physiol. 2016 Apr 15;310(8):F732-F737. doi: 10.1152/ajprenal.00423.2015. Epub 2015 Dec 9.


Tocotrienol-Rich Fraction from Rice Bran Demonstrates Potent Radiation Protection Activity.

Krager KJ, Pineda EN, Kharade SV, Kordsmeier M, Howard L, Breen PJ, Compadre CM, Hauer-Jensen M, Aykin-Burns N.

Evid Based Complement Alternat Med. 2015;2015:148791. doi: 10.1155/2015/148791. Epub 2015 Aug 26.


ROMK (Kir1.1) pharmacology comes of age.

Kharade SV, Swale DR, Denton JS.

Channels (Austin). 2015;9(3):119-20. doi: 10.1080/19336950.2015.1046733. No abstract available.


Cardiac and renal inward rectifier potassium channel pharmacology: emerging tools for integrative physiology and therapeutics.

Swale DR, Kharade SV, Denton JS.

Curr Opin Pharmacol. 2014 Apr;15:7-15. doi: 10.1016/j.coph.2013.11.002. Epub 2013 Nov 26. Review.


The β3 subunit contributes to vascular calcium channel upregulation and hypertension in angiotensin II-infused C57BL/6 mice.

Kharade SV, Sonkusare SK, Srivastava AK, Thakali KM, Fletcher TW, Rhee SW, Rusch NJ.

Hypertension. 2013 Jan;61(1):137-42. doi: 10.1161/HYPERTENSIONAHA.112.197863. Epub 2012 Nov 5.


Intracellular Ca2+ silences L-type Ca2+ channels in mesenteric veins: mechanism of venous smooth muscle resistance to calcium channel blockers.

Thakali KM, Kharade SV, Sonkusare SK, Rhee SW, Stimers JR, Rusch NJ.

Circ Res. 2010 Mar 5;106(4):739-47. doi: 10.1161/CIRCRESAHA.109.206763. Epub 2009 Dec 31.


Sustained release nanoparticulate formulation containing antioxidant-ellagic acid as potential prophylaxis system for oral administration.

Bala I, Bhardwaj V, Hariharan S, Kharade SV, Roy N, Ravi Kumar MN.

J Drug Target. 2006 Jan;14(1):27-34.


Mrg19 depletion increases S. cerevisiae lifespan by augmenting ROS defence.

Kharade SV, Mittal N, Das SP, Sinha P, Roy N.

FEBS Lett. 2005 Dec 19;579(30):6809-13. Epub 2005 Nov 28.

Supplemental Content

Loading ...
Support Center